<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528110</url>
  </required_header>
  <id_info>
    <org_study_id>WuhanU_HIPEC</org_study_id>
    <nct_id>NCT02528110</nct_id>
  </id_info>
  <brief_title>Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Gastric Cancer During Radical Gastrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal
      metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is
      that radical gastrectomy plus HIPEC is superior to only radical gastrectomy in terms of
      overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the efficacy of HIPEC in the treatment of locally advanced gastric cancer,
      patients are randomized into HIPEC group and control group. In HIPEC group, the patients
      undergo radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and 5-Fu.
      Patients in the control group just undergo radical gastrectomy with D2 lymphadenectomy.
      Patients in both groups receive 6 cycles of postoperative chemotherapy (SOX or XELOX) and are
      followed up for 5 years or until death.

      The trial is designed as a prospective, randomized, open, multicenter and parallel group
      study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the date of surgery to the date of death or to the end of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant metastasis rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peritoneal metastasis rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Malignant Neoplasm of Stomach</condition>
  <arm_group>
    <arm_group_label>Radical gastrectomy without HIPEC</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical gastrectomy with HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic intraperitoneal chemotherapy (HIPEC)</intervention_name>
    <description>Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43Â°C, 60min.</description>
    <arm_group_label>Radical gastrectomy with HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 radical gastrectomy</intervention_name>
    <description>radical gastrectomy with D2 lymphadenectomy</description>
    <arm_group_label>Radical gastrectomy without HIPEC</arm_group_label>
    <arm_group_label>Radical gastrectomy with HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SOX postoperative chemotherapy</intervention_name>
    <description>Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.</description>
    <arm_group_label>Radical gastrectomy without HIPEC</arm_group_label>
    <arm_group_label>Radical gastrectomy with HIPEC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>XELOX postoperative chemotherapy</intervention_name>
    <description>Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.</description>
    <arm_group_label>Radical gastrectomy without HIPEC</arm_group_label>
    <arm_group_label>Radical gastrectomy with HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proved diagnosis of locally advanced gastric cancer.

          -  No evidence of distant metastases or peritoneal metastases.

          -  Preoperative examination (CT/MRI) demonstrated resectable gastric cancer with T3-T4
             stage.

          -  Eligible for radical gastrectomy with D2 lymphadenectomy.

          -  Have not received cytotoxic chemotherapy or radiotherapy.

          -  Written informed consent is obtained prior to commencement of trial treatment.

        Exclusion Criteria:

          -  Existence of distant metastasis or peritoneal metastasis during surgery (M1).

          -  Any previous chemotherapy or radiotherapy

          -  Active systemic infections

          -  Inadequate cardiac function, renal function, liver function or bone marrow function at
             the beginning of the trial.

          -  Female patients who are pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan University</investigator_affiliation>
    <investigator_full_name>Bin Xiong, MD</investigator_full_name>
    <investigator_title>Cancer Center of Wuhan University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

